<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358146</url>
  </required_header>
  <id_info>
    <org_study_id>UP2017-04-STELLAR</org_study_id>
    <nct_id>NCT04358146</nct_id>
  </id_info>
  <brief_title>Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)</brief_title>
  <acronym>STELLAR</acronym>
  <official_title>Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula: a Double-blind, Randomized, Controlled, International, Multi-centric Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Statitec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>United Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the effectiveness of this new formula on regurgitations and
      secondarily its effect on digestive tolerance through a randomized, controlled, double-blind
      trial against a comparator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration is 1 month and 2 days. It is possible to add 2 additional months
      (optional).

      The 2 first days (from D-3 to D0) correspond to the pre-selection period. These 2 days are
      followed by the follow-up month (from D0 to D30). It is possible to add an optional follow up
      of 2 months (form D30 to D90).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of regurgitation</measure>
    <time_frame>Day 14</time_frame>
    <description>Decrease of the daily number of regurgitation between baseline and day 14</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Gastroesophageal Reflux in Children</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>new thickened infant formula containing fibres</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>infant formula thickened with locust bean</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental Infant formula</intervention_name>
    <description>Exclusive formula feeding with the new infant formula thickened with fibers</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infant formula thickened with locust bean gum</intervention_name>
    <description>Exclusive formula feeding with the formula thickened with locust bean</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 2 regurgitation episodes per day during the last 2 weeks and ≥ 4 regurgitation
             episodes per day in average during the last 2 days,

          -  exclusive or predominant formula feeding

          -  whose parents signed informed consent

        Exclusion Criteria:

          -  preterm infants or birthweight &lt;2500g

          -  Post enteritis lactose intolerance

          -  Suspected or diagnosed cow's milk protein allergy requiring an eviction diet

          -  Use of medications that may interfere with regurgitation or gastrointestinal transit
             (such as alginates, laxatives, antibiotics...). All these medications have to be
             stopped at least 7 days before inclusion visit (V1)

          -  Infants presenting with any situation which, according to the investigator, may
             interfere with the study participation, or lead to a particular risk for the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Papadopoulou</last_name>
    <role>Study Director</role>
    <affiliation>University of Athens, Athens Children's Hospital &quot;AGIA SOFIA&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bastian CUMINAL</last_name>
    <phone>0033155372222</phone>
    <email>b.cuminal@novalac.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ANNE-SOPHIE GARREAU</last_name>
    <email>as.garreau@novalac.com</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reflux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Locust bean gum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

